Piramal Pharma Solution's business is investing US$188 million for the expansion of its Aurora facility in Canada.
The expansion will add a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients (APIs).
The new facility will utilise ~10,500 sq. ft. of new manufacturing space and will enhance its offerings to customers with this new addition.
It will also support the manufacture of HPAPIs down to an Occupational Exposure Limit (OEL) of 1mcg/ m3.
The expansion will also include two new reactor suites, a dedicated filter dryer room, and a portable filter dryer.
Apart from these, it will also include filtration and drying capabilities that will increase service offerings at the Piramal Pharma Solutions Aurora facility.
The expansion is expected to be completed and be operational by April 30, 2021.